VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA

Project: Research project

Project Details

Description

These investigators propose to clone and sequence the VH regions
from lymphoma-associated immunoglobulin from fresh lymph node tissue from
patients with recurrent lymphoma. They will chose a peptide sequence of 25-mer
from the VH region based on its inclusion of 9 mers having optimal MHC peptide
binding capacity using a bio-informatics approach based on predictions using
binding motifs established for specific HLA-1 alleles expressed by the patient.
The peptide will be synthesized and used to "pulse" dendritic cells enriched
from the peripheral blood generated in vivo by treatment with FLT-3 ligand.
They anticipate that the multiple antigen presenting cell populations within
the DC peripheral blood will process and present a wide spectrum of antigens in
the context of MHC class I leading to a broad CD8 + T cell response generated
against tumor-associated immunoglobulin, and therefore, the tumor. They
anticipate evaluating five patients per year for two years. They will determine
the safety and feasibility of the in vivo generation of DC from peripheral
blood in this patient population, they will determine the safety and
feasibility of vaccination with tumor VH peptide pulsed DC, and determine the
clinical and immunologic response of vaccination with the tumor VH peptide
pulsed DC from peripheral blood from patients with lymphoma.
StatusNot started